Microalbuminuria during cisplatin therapy: Relation with pharmacokinetics and implications for nephroprotection

Anticancer Research

Volumn 20, Issue 5 C, 2000, Pages 3679-3688

  Kern, W ^a   Braess, J ^a   Kaufmann, C C ^a   Wilde, S ^a   Schleyer, E ^a   Hiddemann, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cisplatin; Nephroprotection; Nephrotoxicity; Pharmacokinetics

Indexed keywords

BLEOMYCIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; MICROALBUMINURIA; NEPHROTOXICITY; OSTEOSARCOMA; PRIORITY JOURNAL; PROTECTION; PROTEIN BINDING; PROTEINURIA; SOLID TUMOR; TESTIS CANCER; ULTRAFILTRATION; URINARY EXCRETION;

ADULT; ALBUMINURIA; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; BIOTRANSFORMATION; BONE NEOPLASMS; CISPLATIN; CREATININE; HALF-LIFE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OSTEOSARCOMA; TESTICULAR NEOPLASMS;

EID: 0034536092     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Stability of cisplatin in aqueous solution
2. Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis
3. Long-term effects of chemotherapy in patients with testicular cancer
4. Cisplatin-induced renal toxicity and toxicity-modulating strategies: A review
5. Diagnostic strategy to monitor diabetic nephropathy
6. Proteinuria and hypertension
7. Evaluation of nephrotoxicity secondary to cytostatic agents
8. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus
9. Comparison of renal function parameters in the assessment of cisplatin induced nephrotoxicity
10. Cisplatin nephrotoxicity: Experimental and clinical studies
11. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II)
12. Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors
13. Determination of platinum in plasma of patients affected by inoperable lung carcinoma treated with radiotherapy and concurrent low-dose continuous infusion of cis-dichlorodiammine platinum(II)
14. Cisplatin pharmacokinetics in elderly patients
15. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin
16. Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer
17. Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications
18. Kinetics of cis-dichlorodiammineplatinum
19. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: Preliminary pharmacologic observations
20. Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens
21. High-dose cisplatin in hypertonic saline: Reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics
22. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline
23. Clinical pharmacology of high-dose cisplatin
24. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients
25. Pharmacokinetics of cisplatin and its monohydrated complex in humans
26. Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy
27. Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser
28. Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II)
29. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients
30. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions
31. A phase I trial of 5-day continuous infusion cisplatin and interferon alpha
32. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function
33. Platinum accumulation in adult cancer patients receiving consecutive infusions of cisplatin
34. Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis
35. Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum
36. Two-cycle cisplatin kinetics in patients with ovarian and mammary cancer
37. Kinetics of platinum in cancer patients treated with cisplatin at different doses
38. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity
39. Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II)
40. Cisplatin disposition in children and adolescents with cancer
41. Clinical kinetics on intact cisplatin and some related species
42. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion
43. Platinum accumulation in adult cancer patients receiving cisplatin. Plasma and urinary platinum concentrations on first drug exposure
44. Aclarubicin in single agent and combined chemotherapy of acute myeloid leukaemias
45. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II)
46. Treatment of testicular cancer: A new and improved model
47. Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide
48. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response
49. Pharmacokinetics of cisplatin and its impact on nephrotoxicity during intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer
50. Model building in pharmacokinetics/Part III: Simplified rules for the deduction of analytical solutions for linear compartment models
51. Karnofsky memorial lecture. Ode to methotrexate
52. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells
53. Fluorouracil: Biochemistry and pharmacology
54. Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man
55. Cumulative renal tubular damage associated with cisplatin nephrotoxicity
56. Renal and hepatic concentrations of platinum: Relationship to cisplatin time, dose, and nephrotoxicity
57. Distribution of Pt in the urine and kidney of the cisplatin treated rat
58. A study of the protective effect of chloride salts on cisplatin nephrotoxicity
59. Very-high-dose cisplatin with bleomycin infusion as initial treatment of advanced head and neck cancer
60. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: Failure of hypertonic saline to reduce the nephrotoxicity of cisplatin